Several EGFR Tyr kinase inhibitors (TKIs) have been used as anticancer agents in the treatment of NSCLC in patients with EGFR mutations 43, and EGFR-TKIs show an positive therapeutic effect on EGFR-mutated NSCLC, recurrence and resistance to EGFR TKIs in LUAD patients after curative surgery remains a significant problem and limits the application of EGFR TKIs in NSCLC treatment 44, which leads to a poor prognosis in lung cancer patients. Here, EGFR is linked to non-small cell lung carcinoma.